Vertex Pharmaceuticals price to sales ratio VRTX

Market value divided by revenue over the last twelve months, since 2011.

Today, Oct 23, 2026: 10.6×
10-year median: 11.0×
Against its 10-year history: 46th; percentile: 0 is its lowest day, 100 its highest
10-year range: 6.5× to 20.1×
Peer median: 6.4×

Vertex Pharmaceuticals' price to sales ratio is 10.6× as of Oct 23, 2026.

That is below its ten-year median of 11.0×, close to the middle of its last ten years.

Over that time it ranged from 6.5× in Nov 2021 to 20.1× in Jul 2017.

The median for 8 biotech stocks of a similar size is 6.4×.

Price to sales ratio over time

median 11×

The dashed line is the 10-year median and the shaded band the middle half of its days.

Open the interactive chart, with overlays and comparisons

Year by year

Year	End of year	Low	High
2026 so far	10.6×	8.9×	11.0×
2025	10.0×	8.2×	11.8×
2024	9.9×	9.6×	12.5×
2023	10.9×	8.3×	11.0×
2022	8.5×	7.7×	9.7×
2021	7.8×	6.5×	10.3×
2020	10.3×	9.3×	17.1×
2019	15.7×	12.4×	17.6×
2018	14.6×	14.1×	19.0×
2017	16.5×	11.9×	20.1×
2016	11.0×	11.0×	35.8×
2015	40.7×	33.2×	55.6×
2014	36.2×	12.3×	36.3×
2013	14.4×	5.6×	14.4×
2012	5.1×	4.7×	9.0×
2011	7.6×	6.1×	78.5×

Against its peers

Companies in Biotechnology nearest Vertex Pharmaceuticals' size, closest first, today.

Company	Price to sales ratio
VRTXVertex Pharmaceuticals	10.6×
REGNRegeneron Pharmaceuticals	5.3×
ONCBeOne Medicines	7.0×
ALNYAlnylam Pharmaceuticals	6.2×
UTHRUnited Therapeutics	8.0×
INCYIncyte	4.0×
EXELExelixis	6.6×
NBIXNeurocrine Biosciences	4.3×
HALOHalozyme Therapeutics	8.6×
Peer median	6.4×

Where Vertex Pharmaceuticals ranks

#40of 63Biotech stocks with the lowest price to sales ratio

What the price to sales ratio tells you

Market value divided by revenue over the last twelve months. Useful for companies with little or no profit yet, since sales are harder to make negative than earnings.

Ignores margins entirely. A software company at 10× sales with 30% margins can be cheaper than a grocer at 1× sales with 2% margins.

More on Vertex Pharmaceuticals

Valuation data, not investment advice. Prices as of Oct 23, 2026. Reported figures come from the company's filings with the SEC.